Skip to main content
Article thumbnail
Location of Repository

The clinical effectiveness and cost-effectiveness of bariatric (weight loss) surgery for obesity: a systematic review and economic evaluation

By J. Picot, J. Jones, J.L. Colquitt, E. Gospodarevskaya, E. Loveman, L. Baxter and A.J. Clegg


Objectives: to assess the clinical effectiveness and cost-effectiveness of bariatric surgery for obesity.<br/><br/>Data sources: seventeen electronic databases were searched [MEDLINE; EMBASE; PreMedline In-Process &amp; Other Non-Indexed Citations; The Cochrane Library including the Cochrane Systematic Reviews Database, Cochrane Controlled Trials Register, DARE, NHS EED and HTA databases; Web of Knowledge Science Citation Index (SCI); Web of Knowledge ISI Proceedings; PsycInfo; CRD databases; BIOSIS; and databases listing ongoing clinical trials] from inception to August 2008. Bibliographies of related papers were assessed and experts were contacted to identify additional published and unpublished references<br/><br/>Review methods: two reviewers independently screened titles and abstracts for eligibility. Inclusion criteria were applied to the full text using a standard form. Interventions investigated were open and laparoscopic bariatric surgical procedures in widespread current use compared with one another and with non-surgical interventions. Population comprised adult patients with body mass index (BMI) ? 30 and young obese people. Main outcomes were at least one of the following after at least 12 months follow-up: measures of weight change; quality of life (QoL); perioperative and postoperative mortality and morbidity; change in obesity-related comorbidities; cost-effectiveness. Studies eligible for inclusion in the systematic review for comparisons of Surgery versus Surgery were RCTs. For comparisons of Surgery versus Non-surgical procedures eligible studies were RCTs, controlled clinical trials and prospective cohort studies (with a control cohort). Studies eligible for inclusion in the systematic review of cost-effectiveness were full cost-effectiveness analyses, cost-utility analyses, cost-benefit analyses and cost-consequence analyses. One reviewer performed data extraction, which was checked by two reviewers independently. Two reviewers independently applied quality assessment criteria and differences in opinion were resolved at each stage. Studies were synthesised through a narrative review with full tabulation of the results of all included studies. In the economic model the analysis was developed for three patient populations, those with BMI ? 40; BMI ? 30 and &lt; 40 with Type 2 diabetes at baseline; and BMI ? 30 and &lt;35. Models were applied with assumptions on costs and comorbidity.<br/><br/>Results: a total of 5386 references were identified of which 26 were included in the clinical effectiveness review: three randomised controlled trials (RCTs) and three cohort studies compared surgery with non-surgical interventions and 20 RCTs compared different surgical procedures. Bariatric surgery was a more effective intervention for weight loss than non-surgical options. In one large cohort study weight loss was still apparent 10 years after surgery, whereas patients receiving conventional treatment had gained weight. Some measures of QoL improved after surgery, but not others. After surgery statistically fewer people had metabolic syndrome and there was higher remission of Type 2 diabetes than in non-surgical groups. In one large cohort study the incidence of three out of six comorbidities assessed 10 years after surgery was significantly reduced compared with conventional therapy. Gastric bypass (GBP) was more effective for weight loss than vertical banded gastroplasty (VBG) and adjustable gastric banding (AGB). Laparoscopic isolated sleeve gastrectomy (LISG) was more effective than AGB in one study. GBP and banded GBP led to similar weight loss and results for GBP versus LISG and VBG versus AGB were equivocal. All comparisons of open versus laparoscopic surgeries found similar weight losses in each group. Comorbidities after surgery improved in all groups, but with no significant differences between different surgical interventions. Adverse event reporting varied; mortality ranged from none to 10%. Adverse events from conventional therapy included intolerance to medication, acute cholecystitis and gastrointestinal problems. Major adverse events following surgery, some necessitating reoperation, included anastomosis leakage, pneumonia, pulmonary embolism, band slippage and band erosion. Bariatric surgery was cost-effective in comparison to non-surgical treatment in the reviewed published estimates of cost-effectiveness. However, these estimates are likely to be unreliable and not generalisable because of methodological shortcomings and the modelling assumptions made. Therefore a new economic model was developed. Surgical management was more costly than non-surgical management in each of the three patient populations analysed, but gave improved outcomes. For morbid obesity, incremental cost-effectiveness ratios (ICERs) (base case) ranged between £2000 and £4000 per QALY gained. They remained within the range regarded as cost-effective from an NHS decision-making perspective when assumptions for deterministic sensitivity analysis were changed. For BMI ? 30 and &lt; 40, ICERs were £18,930 at two years and £1397 at 20 years, and for BMI ? 30 and &lt;35, ICERs were £60,754 at two years and £12,763 at 20 years. Deterministic and probabilistic sensitivity analyses produced ICERs which were generally within the range considered cost-effective, particularly at the long twenty year time horizons, although for the BMI 30-35 group some ICERs were above the acceptable range.<br/><br/>Conclusions: bariatric surgery appears to be a clinically effective and cost-effective intervention for moderately to severely obese people compared with non-surgical interventions. Uncertainties remain and further research is required to provide detailed data on patient QoL; impact of surgeon experience on outcome; late complications leading to reoperation; duration of comorbidity remission; resource use. Good-quality RCTs will provide evidence on bariatric surgery for young people and for adults with class I or class II obesity. New research must report on the resolution and/or development of comorbidities such as Type 2 diabetes and hypertension so that the potential benefits of early intervention can be assessed

Topics: RD
Year: 2009
OAI identifier:
Provided by: e-Prints Soton
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles


    1. (2009). A decade of change in obesity surgery. National Bariatric Surgery Registry (NBSR) Contributors. doi
    2. A prospective study of body mass index, weight change, and risk of stroke in women.
    3. Bariatric surgery: crossing a body mass index threshold. doi
    4. (1992). Changes in gallbladder bile composition following gallstone formation and weight reduction.
    5. Clinical and cost effectiveness of surgery for morbid obesity: a systematic review and economic evaluation. doi
    6. Counting the costs of overweight and obesity: modeling clinical and cost outcome. Curr Med Res 2006;22:575–86. 177. Curtis L. Unit costs of health and social care. doi
    7. (2000). Current practices in the prophylaxis of venous thromboembolisms in bariatric surgery. doi
    8. (2006). Department of Health. NHS Reference Costs
    9. (2005). Estimating utility values for health states of overweight and obese individuals using the SF-36. QoL Res doi
    10. (2005). Evaluation of the association between the EQ-5D index (health related utility) and body mass index (obesity) in hospital-treated people with type 1 diabetes, type 2 diabetes and with no diagnosed diabetes. Diabet Med doi
    11. (1985). Gallbladder disease in morbidly obese. doi
    12. (2003). Gallstone formation prophylaxis after gastric restrictive procedures for weight loss. a randomized double-blind placebo-controlled trial. Ann Surg doi
    13. (1984). Gastric bypass and gastric partitioning in morbid obesity: results of a controlled trial [abstract].
    14. (1987). Horizontal or vertical banded gastroplasty after pretreatment with very-low-calorie formula diet: a randomized trial.
    15. (1987). Incidence of symptomatic gallstones after bariatric operations. Surg Gynecol Obstet
    16. Modelling EuroQol healthrelated utility values for diabetic complications from CODE-2 data. doi
    17. (1987). Risk factors for coronary heart disease in African Americans: the atherosclerosis risk in communities study, doi
    18. (1996). The ‘Utility’ of the visual analog scale in medical decision making and technology assessment: is it an alternative to the time tradeoff? doi
    19. (2003). The economic burden of stroke in the United Kingdom. Pharmacoeconomics doi
    20. The health-related utility and health-related quality of life of hospitaltreated subjects with Type I and Type 2 diabetes with particular reference to differing severity of peripheral neuropathy. doi
    21. (2008). The impact of body weight on patient utilities with or without type 2 diabetes: a review of the medical literature. Value Hlth doi
    22. Trends in mortality in bariatric surgery: a systematic review and meta-analysis. doi
    23. (2004). Utility values for obesity and preliminary analysis of the health outcomes data repository. Exp Rev Pharmacoecon Outcomes Res doi
    24. Weight loss with self-help compared with a structured commercial program: a randomised trial. doi

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.